Literature DB >> 9461566

Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases.

J M English1, G Pearson, R Baer, M H Cobb.   

Abstract

Extracellular signal-regulated protein kinase 5 (ERK5) is a recently discovered orphan mitogen-activated protein kinase for which no substrates or strong activators have been described. Two ERK5 chimeras were created as a novel approach to discover its substrates and upstream regulators. One chimeric protein contained the N-terminal domain of the ERK5 catalytic core (subdomains I-IV) and the C-terminal domain of the ERK2 catalytic core (subdomains V-XI). This chimera was highly responsive to stimuli that regulate ERK2 in vitro and in cells. A second chimeric protein consisted of the N-terminal domain of ERK2 (subdomains I-IV) and the C-terminal domain of the ERK5 catalytic core (subdomains V-XI). This chimera was activated in bacteria by coexpression with a constitutively active mutant of MEK1. Using the activated chimera, we identified three in vitro substrates of ERK5. Assaying ERK5 activity in immune complexes with one of these substrates, c-Myc, we determined that the ERK5 catalytic domain is activated by V12 H-Ras and to a lesser extent by phorbol ester but not by constitutively active mutants of Raf-1. Thus, ERK5 is a target of a novel Ras effector pathway that may communicate with c-Myc.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9461566     DOI: 10.1074/jbc.273.7.3854

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signaling.

Authors:  M T Diaz-Meco; J Moscat
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 2.  The atypical protein kinase Cs. Functional specificity mediated by specific protein adapters.

Authors:  J Moscat; M T Diaz-Meco
Journal:  EMBO Rep       Date:  2000-11       Impact factor: 8.807

3.  ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation.

Authors:  G Pearson; J M English; M A White; M H Cobb
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

4.  Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.

Authors:  Matthew S Squires; Paula M Nixon; Simon J Cook
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

5.  Nuclear β-adrenergic receptors modulate gene expression in adult rat heart.

Authors:  George Vaniotis; Danny Del Duca; Phan Trieu; Charles V Rohlicek; Terence E Hébert; Bruce G Allen
Journal:  Cell Signal       Date:  2010-08-21       Impact factor: 4.315

Review 6.  The ERK cascade: a prototype of MAPK signaling.

Authors:  Hadara Rubinfeld; Rony Seger
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

7.  CK2alpha/CK1alpha chimeras are sensitive to regulation by the CK2beta subunit.

Authors:  Ana Jedlicki; Catherine C Allende; Jorge E Allende
Journal:  Mol Cell Biochem       Date:  2008-07-12       Impact factor: 3.396

Review 8.  Oncogenic signaling of MEK5-ERK5.

Authors:  Van T Hoang; Thomas J Yan; Jane E Cavanaugh; Patrick T Flaherty; Barbara S Beckman; Matthew E Burow
Journal:  Cancer Lett       Date:  2017-01-30       Impact factor: 8.679

9.  De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis.

Authors:  Kyung-Sun Heo; Eugene Chang; Nhat-Tu Le; Hannah Cushman; Edward T H Yeh; Keigi Fujiwara; Jun-ichi Abe
Journal:  Circ Res       Date:  2013-02-04       Impact factor: 17.367

10.  Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex.

Authors:  Tatiana Erazo; Ana Moreno; Gerard Ruiz-Babot; Arantza Rodríguez-Asiain; Nicholas A Morrice; Josep Espadamala; Jose R Bayascas; Nestor Gómez; Jose M Lizcano
Journal:  Mol Cell Biol       Date:  2013-02-19       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.